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ABSTRACT
Novel systemic treatments for hepatocellular carcinoma (HCC) are strongly needed. Immunotherapy is a
promising strategy that can induce speciﬁc antitumor immune responses. Understanding the mechanisms
of immune resistance by HCC is crucial for development of suitable immunotherapeutics. We used
immunohistochemistry on tissue-microarrays to examine the co-expression of the immune inhibiting
molecules PD-L1, Galectin-9, HVEM and IDO, as well as tumor CD8C lymphocyte inﬁltration in HCC, in two
independent cohorts of patients. We found that at least some expression in tumor cells was seen in 97%
of cases for HVEM, 83% for PD-L1, 79% for Gal-9 and 66% for IDO. In the discovery cohort (n D 94), we
found that lack of, or low, tumor expression of PD-L1 (p < 0.001), Galectin-9 (p < 0.001) and HVEM
(p < 0.001), and low CD8CTIL count (p D 0.016), were associated with poor HCC-speciﬁc survival. PD-L1,
Galectin-9 and CD8CTIL count were predictive of HCC-speciﬁc survival independent of baseline
clinicopathologic characteristics and the combination of these markers was a powerful predictor of HCC-
speciﬁc survival (HR 0.29; p <0.001). These results were conﬁrmed in the validation cohort (n D 60). We
show that low expression levels of PD-L1 and Gal-9 in combination with low CD8CTIL count predict
extremely poor HCC-speciﬁc survival and it requires a change in two of these parameters to signiﬁcantly
improve prognosis. In conclusion, intra-tumoral expression of these immune inhibiting molecules was
observed in the majority of HCC patients. Low expression of PD-L1 and Galectin-9 and low CD8CTIL count
are associated with poor HCC-speciﬁc survival. Combining immune biomarkers leads to superior
predictors of HCC mortality.
Abbreviations: AFP, a fetoprotein; AMC, Amsterdam Medical Center; EMC, Erasmus MC-University Medical Center;
Gal-9, galectin-9; HCC, hepatocellular carcinoma; TFL, tumor-free liver; TIL, tumor-inﬁltrating lymphocytes; TMA,
tissue microarray
KEYWORDS
Galectin-9; hepatocellular
carcinoma; HVEM; IDO;
PD-L1; tissue microarrays;
tumor-inﬁltrating
lymphocytes
Introduction
Hepatocellular carcinoma (HCC) is a leading cause of cancer-
related death.1 Curative treatments such as resection, local abla-
tion or liver transplantation are only applicable in the 20% of
patients with early stage disease.2 For selected patients with
advanced disease median survival can be modestly extended
with the use of sorafenib.3 However, cure at this stage is no lon-
ger possible.
Immunotherapeutic strategies, such as tumor vaccination,
adoptive cell therapy and immune modulating antibodies, may
provide alternative therapeutic options in HCC.4,5 Indeed,
immune modulating inhibitors against CTLA-4 (Ipilimumab)
or PD-1 (Nivolumab, Pembrolizumab) and PD-L1 (Atezolizu-
mab) have already been approved for various cancers such as
melanoma, lung, kidney and bladder cancer.6-10 These so-called
immune checkpoint inhibitors interrupt immune resistance
mechanisms exploited by tumors to evade natural antitumor
immunity. Reported immune resistance mechanisms include,
among others, the expression of molecules that suppress intra-
tumoral T-cell responses by ligating inhibitory receptors on T
cells, such as PD-L1, galactin-9 and HVEM and the expression
of enzymes that generate T-cell inhibitory metabolites, such as
IDO.11
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Binding of PD-L1 to its receptor PD-1, on activated T cells,
suppresses T-cell responses.12 PD-L1 is expressed in numerous
tumors, including HCC, and in-vitro abrogation of the
PD-1/PD-L1 interaction has been shown to reinvigorate
tumor-speciﬁc responses of T-cells isolated from HCC
patients.13-19 Galectin-9 (Gal-9) is a carbohydrate-binding pro-
tein that is involved in T-cell homeostasis.20 Contrasting effects
of Gal-9 on antitumor immunity have been described. On the
one hand binding of Gal-9 to its receptor TIM-3, expressed on
activated T cells, causes T-cell dysfunction and apoptosis in
tumors,21 while binding of Gal-9 to CD44 promotes the differ-
entiation of T-regulatory cells.22 Conversely, Gal-9 can enhance
T-helper 1 type antitumor immunity,23 inhibit NK cell chemo-
taxis to the tumor microenvironment24 and exert anti-meta-
static potential on tumor cells.25,26 Like PD-L1, Gal-9 is
expressed in several cancers, including HCC.21,27 HVEM is a
“molecular switch” with dual immune-stimulatory and inhibi-
tory functions.28 By ligation of LIGHT, HVEM stimulates T-
cell responses, while binding to BTLA or CD160 leads to inhi-
bition of T-cells. HVEM is known to be expressed in mela-
noma29 and most recently in HCC.30 IDO is the rate-limiting
enzyme in the catabolism of the essential amino-acid trypto-
phan.31 Tryptophan depletion, as well as accumulation of tryp-
tophan catabolites such as kynurenine, induce T-cell anergy
and apoptosis. IDO inhibitors are currently in clinical develop-
ment. IDO expression has been demonstrated in several cancer
types, including HCC.32
As clinical efﬁcacy of immune checkpoint antibodies seems
dependent on expression of their target molecules in
tumors33,34 knowledge of their expression patterns in HCC
may establish which of these molecules, or combinations, might
be promising to target. No published study has systematically
examined co-expression of multiple immune inhibitory mole-
cules in a homogeneous cohort of HCC patients before. Thus,
the primary aim of the present study was to examine the pat-
terns of co-expression, as well as the relationship with the
tumor-inﬁltrating lymphocytes (TIL) and cancer-related sur-
vival, of several immune inhibitory molecules in HCC tumor
tissue and adjacent non-tumorous tissue. PD-L1, Gal-9, HVEM
and IDO were chosen for study because their mechanism of
interaction with the immune system is generally understood
while at the same time a reliable primary antibody is available.
Tissue microarrays were constructed, and expression of the
above molecules on tumor cells and hepatocytes was examined,
by immunohistochemistry, in two separate patient cohorts.
Patients and methods
Patient population and tissue samples
Archived formalin ﬁxed parafﬁn-embedded tissue samples
from 154 patients who underwent hepatic resection for HCC at
Erasmus MC-University Medical Center (EMC, n D 94) or
Amsterdam Medical Center (AMC, n D 60), between June
2001 and July 2014, were used for this study. Fresh frozen tis-
sue, which was available from 20 additional patients, was used
for RNA extraction. Patients with HCC were selected for the
study if they had undergone surgery with curative intent. Clini-
cal information was collected retrospectively from the
electronic record. The clinical information collected included
etiologic factors, HCC recurrence, patient death, cause of death,
as well as known prognostic clinicopathologic characteristics,
such as tumor differentiation, vascular invasion, number of
lesions, largest tumor size and pre-surgical a-fetoprotein (AFP)
level. The study was approved by the local medical ethical com-
mittee. In addition, the study protocol conforms to the ethical
guidelines of the 1975 Declaration of Helsinki.
Tissue microarray (TMA) construction
Three or four 0.6 mm cores were taken from the tumorous area
of 154 patients and two 0.6 mm cores were taken from the cor-
responding tumor-free liver (TFL) area of 133 of these patients.
Areas with vital tumor and TFL tissue were marked by experi-
enced pathologists (KB or JV) using archived H&E glass slides.
The TMAs were made using either an automated tissue-arrayer
ATA-27 (Beecher Instruments, Silver Springs MD, USA) or a
fully manual tissue-arrayer MTA-1 (Beecher Instruments).
Immunohistochemistry and scoring
Complete information on the immunohistochemistry protocols
can be found in the supplementary methods section. Complete
information on the primary antibodies used can be found in
Table S1. Scoring was performed by two independent investiga-
tors (KS and HS) blinded to clinical outcome and differences
resolved by mutual agreement. Scoring was performed on can-
cer cells (tumor cores) or hepatocytes (TFL cores). Intensity
was scored in a scale from zero to three. Intra-core heterogene-
ity of staining intensity of tumor cells or hepatocytes was rarely
observed in our cohort, thus only staining intensity was taken
into consideration. In the case of CD8C staining, the positive
cells per core were counted manually and average counts were
used for analysis.
PCR ampliﬁcation
All primers for the target genes were intron spanning and
sequences are listed in Table S2. The RT-PCR ampliﬁcation
technique and primer sources are described in detail in the sup-
plementary methods section.
Statistical analysis
All analysis was performed in duplicate. The discovery phase
was performed in the EMC cohort while the validation phase
was performed in the AMC cohort. The differences in expres-
sion of immune inhibitory molecules between tumor and TFL
tissue was analyzed with the paired T-test. The associations
between clinicopathologic parameters with the expression of
immune inhibitory molecules, as well as the co-expression of
the immune inhibiting molecules with each other, were exam-
ined using the x2 tests or the T-test as appropriate. Survival
(time to recurrence or HCC-speciﬁc survival) was calculated
from the date of surgery to the date of event (recurrence or
death from HCC, respectively), or the date of last follow-up.
Patients lost to follow-up were censored as of the last day of fol-
low-up. Patients who died from causes other than HCC were
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censored at the date of death. Survival curves were estimated by
the Kaplan-Meier method. For sensitivity analysis, the survival
analysis was repeated by excluding the patients who died from
post-surgical complications within 3 mo after surgery. Optimal
high vs. low values were established by examining a grid of cut-
offs and choosing the cutoff with the lowest ¡2 log likelihood,
taking into consideration to maximize the proportion of
patients identiﬁed by the cutoff value when possible. The Bre-
slow test was used to asses differences between survival curves
of different groups, while for parameters with three or four lin-
early associated levels the linear trend for factor levels was
used. Given that we examined the expression of ﬁve individual
parameters (PD-L1, Gal-9, HVEM, IDO, CD8CTIL count)
Bonferroni’s correction required a p-value of < 0.01 for statisti-
cal signiﬁcance in the discovery cohort. For multivariate analy-
sis, the Cox proportional Hazard regression analysis was used.
The statistical analysis was performed using the SPSS© 21
software.
Results
Patient cohorts and baseline clinicopathologic
characteristics
Clinicopathologic characteristics of patients in the EMC discov-
ery cohort and the AMC validation cohort can be seen in
Table 1, while complete information on etiology of liver disease
can be found in Table S3. Median time to recurrence and over-
all survival were 19.4 mo and 37.2 mo for the EMC cohort and
Table 1. Patient characteristics.
Characteristics
Discovery cohort
N D 94
Validation cohort
N D 60
Male/Female (%) 63/31 (67/33) 48/12 (80/20)
Hepatitis-Ba/Hepatitis-Cb (%) 23/11 (25/12) 14/19 (23/32)
Cirrhosis (%) 32 (34) 20 (33)
Tumor differentiation (1–3) 26/47/20 (28/50/22) 15/34/10 (25/58/17)
Vascular invasion 58 (68) 13 (42)
Single lesions (%) 72 (77) 50 (83)
Median size (Range) 5.9 cm (0.5–25.0) 5.0 cm (1.0–29.0)
Median AFP (Range) 8.5 ug/L (1–63.000) 9.0 ug/L (2–29.000)
Recurrence 50 (53) 28 (47)
Death 44 (47) 21 (35)
HCC-related death 29 (31) 13 (22)
aHBsAg(C) and/or anti-HBc positive; banti-HCV positive; There is statistically sig-
niﬁcant more Hepatitis-C in the AMC cohort and vascular invasion in the EMC
cohort.
Figure 1. Representative stainings of tumor tissues and corresponding TFL tissues, positive control tissues and normal liver. Positive controls tissues shown are placenta
for PDL1, pancreatic cancer for HVEM and tonsil for Gal-9, IDO and CD8. The positive control tissues stain as expected from prior literature. Note the hepatocyte staining
seen for all molecules (except CD8C) in the TFL tissue area and the general lack of hepatocyte staining in normal liver tissue. For Gal-9 characteristic Kupffer cell staining
can be seen in the normal liver tissue.
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23.5 mo and 31.8 mo for the AMC cohort. Recurrence was
seen in 78 patients while 42 patients died from HCC. A com-
plete list with the causes of death can be found in Table S4.
From the known clinicopathologic prognostic factors an AFP
level above 400 mgL¡1 (p D 0.002), multiple lesions (p D 0.043)
and tumor size >3 cm (p D 0.024) were associated with poor
HCC-speciﬁc survival in the combined cohort (Fig. S1). Tumor
grade and vascular invasion were not associated with HCC-spe-
ciﬁc survival.
Description of immune inhibitory molecule expression in
the combined cohorts
Fig. 1 shows representative stainings in tumor tissue, TFL tis-
sue, positive control tissues and healthy liver tissues, while
Fig. S2 shows examples of various expression levels observed in
tumor tissues, for all the molecules examined in our study. At
least some cytoplasmatic expression in tumor cells was seen in
82.9% of cases for PD-L1, 78.8% for Gal-9, 96.6% for HVEM
and 66.4% for IDO. In addition to their expression in the tumor
tissues, PD-L1, Gal-9, HVEM and IDO were also expressed by
hepatocytes in the surrounding TFL tissue. At least some cyto-
plasmatic expression in hepatocytes, in TFL tissue, was seen in
95.8% of cases for PD-L1, 93.5% for Gal-9, 100% for HVEM
and 92.6% for IDO. No relationship was found between the
expression of any molecule in tumor, or in the TFL tissue, with
etiologic factors, or other clinicopathologic characteristics, after
Bonferroni correction (Table S5). Tumor expression correlated
with TFL tissue expression in all cases. Fig. 2 depicts the level
of expression of each molecule in tumor cells and in hepato-
cytes in the corresponding TFL tissues for the combined
cohort. Note that there is a statistically signiﬁcant under-
expression of all molecules in the tumor tissue. To conﬁrm that
these molecules are indeed expressed in TFL tissues, we quanti-
ﬁed mRNA expression in paired tumor and TFL tissues of 20
resected HCC patients, from which fresh frozen tissue was
available. In Fig. S3, we show that mRNA encoding for all these
immune molecules is indeed expressed in the TFL tissues, at
levels comparable to the levels seen in the tumor tissues. Our
results indicate that the investigated immune inhibitory mole-
cules are frequently expressed not only in the tumor but also in
the TFL compartment of HCC patients.
Immune inhibitory molecule expression: Association with
survival and recurrence in the discovery (EMC) cohort
Next, we investigated the relationship between immune inhibi-
tory molecule expression and survival in the EMC cohort. Opti-
mal cut-offs for low versus high staining were made as
described in the statistical methods. Patients were considered
to have low PD-L1 (n D 16) or Gal-9 (n D 18) staining when
there was complete absence of staining, while low HVEM
included patients with either complete absence of staining or
very faint staining (n D 9). Low IDO (n D 63) included patients
with complete absence, or at most C1, staining intensity. We
found that expression in tumor tissue, but not in surrounding
TFL tissue, was signiﬁcantly associated with HCC-speciﬁc sur-
vival for three out of the four molecules examined (Fig. 3A).
Speciﬁcally, no or low tumor expression of PD-L1 (p < 0.001),
Gal-9 (p < 0.001) and HVEM (p < 0.001) was associated with
poor HCC-speciﬁc survival, while expression of IDO was not
associated with HCC-speciﬁc survival (p D 0.953). Hazard
ratios and 95% conﬁdence intervals can be found in Table 2. In
addition, we quantiﬁed the numbers of CD8CTIL. The relation-
ship of CD8CTIL count with HCC-speciﬁc survival was not sig-
niﬁcant after Bonferroni’s correction (p D 0.016). For HCC
Figure 2. Comparison of protein expression levels of PD-L1, Gal-9, HVEM and IDO in the tumor tissues and the corresponding TFL tissues in the combined cohort. Boxplots
representing protein expression in tumor cells vs. TFL tissue. p values were determined by the paired T-test.
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recurrence the relationship with expression of these molecules
followed the same trends (Fig. S4). Low tumor expression of
PD-L1 (p < 0.001), Gal-9 (p D 0.009), HVEM (p D 0.004), and
also low CD8CTIL count (p D 0.007) were signiﬁcantly
associated with shorter time to HCC recurrence, while tumor
expression of IDO was not associated with recurrence after
Bonferroni’s correction (p D 0.029). The results did not differ
when analyses was performed by excluding the nine patients
who died at EMC in the post-surgical period from causes other
than HCC.
Based on a multivariate analysis, where all parameters with p
values < 0.02 were entered in a single model, we derived that
tumor expression of PD-L1, Gal-9, CD8CTIL count, AFP level
and number of lesions were independent predictors of HCC-
speciﬁc survival in the EMC cohort (Table 2). HVEM was not
independently associated with HCC-speciﬁc survival when
examined together with the other immune parameters.
Because of the ability of the immune inhibitory molecules to
predict HCC-speciﬁc survival, we wondered whether combin-
ing all three independently prognostic immune parameters
Table 2. Cox-proportional hazard regression analysis of patients’ HCC-speciﬁc sur-
vival in the discovery cohort.
Univariate Multivariate
Variables HR 95% CI p-value HR 95% CI p-value
AFP>100 ug/L 2.67 1.17–6.13 0.020 4.83 1.85–12.6 0.001
One vs. multiple lesions 3.53 1.63–7.67 0.001 2.37 1.01–5.56 0.048
PD-L1 0.19 0.86–0.43 <0.001 0.30 0.13–0.72 0.007
Gal-9 0.31 0.15–0.66 0.003 0.33 0.14–0.80 0.014
HVEM 0.21 0.09–0.50 <0.001 0.50 0.20–1.25 0.718
CD8CTIL count 0.22 0.05–0.93 0.040 0.18 0.04–0.82 0.027
Figure 3. HCC-speciﬁc survival Kaplan-Meier curves of PD-L1, Gal-9, HVEM, IDO and CD8CTIL count in the tumor and TFL compartment. (A) Survival curves in relation to
tumor expression for the discovery (EMC) cohort. (B) Survival curves in relation to tumor expression for the validation (AMC) cohort. (C) Survival curves in relation to tumor
expression for the combined cohorts. (D) Survival curves in relation to TFL tissue expression for the combined cohorts. Optimal high vs. low values were established by
examining a grid of cutoffs and choosing the cutoff with the lowest¡2 log likelihood. For determination of the p values the Breslow test was used.
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would improve the prediction. Fig. 4 shows that low levels of
two or three of these parameters in tumor tissue predicts poor
survival, while low level of none, or only one, parameter pre-
dicts good HCC-speciﬁc survival. Concordantly, the
combination of PD-L1, Gal-9 and CD8CTIL as a single bio-
marker was a powerful independent predictor of HCC-speciﬁc
survival in multivariate analysis (p < 0.001, HR 0.29, 95%CI
0.18–0.48).
Figure 4. HCC-speciﬁc survival Kaplan-Meier curves of the combined PD-L1, Gal-9 and CD8CTIL count biomarker. Combination of PD-L1, Gal-9 and CD8CTIL count in rela-
tion to HCC-speciﬁc survival in the discovery (EMC) cohort, validation (AMC) cohort and combined cohort. For determination of the p values the linear trend for factor lev-
els was used.
e1273309-6 K. SIDERAS ET AL.
D
ow
nl
oa
de
d 
by
 [E
ras
mu
s U
niv
ers
ity
] a
t 0
6:4
9 0
3 N
ov
em
be
r 2
01
7 
Validation in the AMC cohort
External validation of the above ﬁndings was performed in the
cohort from AMC. Low tumor expression of PD-L1 (p D
0.010) and Gal-9 (p D 0.047) were also signiﬁcantly associated
with poor HCC-speciﬁc survival (Fig. 3B). Low tumor
CD8CTIL count showed a trend toward poor HCC-speciﬁc sur-
vival (p D 0.092), with a hazard ratio (HR 0.36, 95%CI 0.08–
1.64) that was of similar magnitude and direction as in the dis-
covery (EMC) cohort (HR 0.22, 95%CI 0.05–0.93). The combi-
nation of PD-L1, Gal-9 and CD8CTIL as a single biomarker
(Fig. 4) predicted HCC-speciﬁc survival (p D 0.020, HR 0.43,
95%CI 0.24–0.77) and was validated as an independent predic-
tor of HCC-speciﬁc survival in multivariate analysis in the
AMC cohort (p D 0.005).
Co-expression patterns and survival
Low levels of expression of either PD-L1, Gal-9 or HVEM were
signiﬁcantly associated with low levels of expression of the
other two ligands (Table S6). Such a relationship was not seen
with IDO. The CD8CTIL count showed a signiﬁcant but weak
correlation with PD-L1 expression (p D 0.046) but not with
Gal-9, HVEM or IDO. Speciﬁcally, high expression of PD-L1
was correlated with a high CD8CTIL count and vice-versa.
Having established the predictive power of the individual
and combined expression of immune inhibitory molecules, we
wondered how the relationship of each molecule to survival
related to tumor lymphocyte inﬁltration. It has been previously
shown that tumor expression of PD-L1 in melanoma carries
different prognostic values in the setting of high vs. low TIL
counts.33,35 Fig. 5A shows that low PD-L1 tumor expression in
combination with low CD8CTIL count is associated with very
poor HCC-speciﬁc survival, while high PD-L1 and high
CD8CTIL count is associated with good HCC-speciﬁc survival
(p < 0.001, HR 0.29, 95%CI 0.17–0.50). The presence of either
high PD-L1 or high CD8CTIL count alone is associated with
intermediate survival. A similar observation was made for the
combination of Gal-9 tumor expression and CD8CTIL count
(p < 0.001, HR 0.29, 95%CI 0.17–0.49) (Fig. 5B).
Discussion
In two independent cohorts, we found that low tumor expres-
sion of PD-L1 and Gal-9, as well as low CD8CTIL count, are
independent predictors of poor HCC-speciﬁc survival. HVEM
expression, on the other hand, while individually an indepen-
dent predictor of HCC-speciﬁc survival, was not independent
when other immune parameters were taken into consideration.
The combination of tumor PD-L1 and Gal-9 expression and
CD8CTIL count appeared to be a powerful independent predic-
tor of HCC-speciﬁc survival. We show that there is a group of
patients with extremely poor prognosis who express low levels
of PD-L1 and Gal-9 and have low CD8CTIL count. It requires
a change in two of these parameters to signiﬁcantly affect
prognosis.
Similar to our results, low expression of PD-L1 was found to
be associated with poor survival in melanoma,33 gastrointesti-
nal-stromal tumors,36 colorectal cancer,37 and non-small cell
lung cancer.38 On the other hand, other studies in melanoma,39
colorectal40 and renal cell cancer41 have shown the opposite.
Moreover, in a third melanoma study,42 and in studies in squa-
mous-cell lung cancer,43 urothelial cancer44 and breast can-
cer,45 tumor PD-L1 expression has shown no prognostic
signiﬁcance. In addition, and in contrast to our results, two
prior studies in HCC have suggested that lower PD-L1 expres-
sion is associated with better survival,15,18 while one recent
study reported that lower PD-L1 staining is associated with bet-
ter 2-y chance of recurrence.46 These conﬂicting results on the
association between PD-L1 expression and prognosis, are prob-
ably related to the lack of speciﬁcity of several anti-PD-L1 anti-
bodies for immunohistochemical staining of PD-L1 in
formalin-ﬁxed parafﬁn-embedded tissues.15,18,38,39,42 Speciﬁ-
cally, in the study by Gao et al.,15 the PD-L1 clone MIH1 was
used on parafﬁn-embedded HCC tissue. This particular clone
has been shown to be non-speciﬁc on parafﬁn embedded tissue
in prior studies.38,42 To further conﬁrm these prior observa-
tions, we stained several control tissues and TMA cores with
the MIH1 clone and compared the ﬁndings to our results. We
show, in Fig. S5, that the MIH1 clone failed to properly stain
placenta and tonsil tissue, and also provides positive stainings
of tumor cores that were found to be negative for PD-L1 using
Figure 5. HCC-speciﬁc survival Kaplan-Meier curves of tumor PD-L1 and Gal-9 expression in relation to CD8CTIL count in the combined cohorts. (A) Combination of PD-L1
and CD8CTIL count in relation to HCC-speciﬁc survival. (B) Combination of Gal-9 and CD8CTIL count in relation to HCC-speciﬁc survival. For determination of the p values
the linear trend for factor levels was used.
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the 9A11 antibody clone. Importantly, the anti-PD-L1 antibody
that we used (clone 9A11) has been extensively validated for
this purpose,41,44,47,48 and we show that it provides the correct
staining pattern in control tissues, namely selective staining of
the syncytiotrophoblast layer in placenta tissue and staining of
the crypt regions in tonsil tissue (Figs. 1 and Fig. S5). Moreover,
in a previous study,49 we showed that this antibody gives simi-
lar, but more intense, staining patterns as the well-validated
5H1 clone.50 The use of imaging software to analyze PD-L1
density, as performed in the studies by Gao et al. and Wu et al.,
is another possible explanation for the differing results.15,18
Imaging software can inadvertently include expression of PD-
L1 by stroma and TIL, in addition to tumor. Differences in the
characteristics of the included patients, may be another factor.
For example, the study of Calderaro et al.46 that examined a
large cohort of patients using another validated antibody anti-
PD-L1 antibody, did not report on long-term mortality end-
points, while information on recurrence was available in a little
over half the patients, making direct comparisons with our
study not possible. Finally, it is well known that both cytoplas-
matic and membranous PD-L1 staining has been described in
various cancers, and we are not the ﬁrst to describe a pre-domi-
nance of cytoplasmatic staining over membranous staining for
PD-L1. In fact, studies using well-validated antibodies have
demonstrated both types of staining in various cancers
before33,50 and other prior studies in HCC have also predomi-
nately demonstrated cytoplasmatic staining.16 It has recently
been hypothesized that cytoplasmatic tumor staining represents
intracellular stores of PD-L1 ready to be transported to the
membrane upon contact with immune cells.33 Alternatively,
cytoplasmic PD-L1 may be released as a functional soluble mol-
ecule into the extracellular microenvironment.51
Regarding the prognostic signiﬁcance of Gal-9 expression in
tumors there is more consensus. Similar to our ﬁndings, under-
expression of Gal-9 has been associated with poor outcome in
HCC,27 and also in melanoma, breast, cervical and gastric can-
cers.25,26,52,53 However, one recently published study in renal
cell cancer54 showed the opposite. It is possible that the signiﬁ-
cance of expression of Gal-9 may be tumor speciﬁc. In renal
cell cancer, for example, the results for both PD-L1 and Gal-9
are opposite to ours.41,54
One may wonder why low expression of these molecules sig-
niﬁes high risk of HCC death, since their expression in itself is
supposed to inhibit effector immune responses. It is known
that several of these molecules are overexpressed in response to
IFNg and TIL inﬁltration, a process called adaptive immune
resistance.33,55-57 Therefore, expression of immune inhibitory
molecules in cancer cells may not only be induced by intrinsic
mechanisms (i.e., mutations, epigenetics e.c.t.) but also by
tumor-inﬁltrating immune cells. Probably, their presence in the
tumor microenvironment reﬂects an active immunologic attack
that is beneﬁcial to patients. Low or no expression of such mol-
ecules could indicate that the cancer is beyond detection by the
immune system or that the antitumor immune response is
ineffective.
Several studies have shown that expression of PD-L1 is asso-
ciated with TIL inﬁltration in various cancers.33,38,43 Our study
is the ﬁrst to describe this association in HCC. Stratiﬁcation of
tumors, based on the expression of PD-L1 and the presence or
absence of TILs, has been recently proposed.33,35 We show that
HCC patients with low tumor PD-L1 expression and CD8CTIL
inﬁltration (type II tumors), which suggests tumors with
immune ignorance, according to the model by Teng et al.,35
have the worst prognosis (Fig. 5A), whereas patients with high
tumoral PD-L1 expression and TIL inﬁltration (type I tumors),
which suggest adaptive immune resistance, have the best prog-
nosis, as predicted. Taken together, our data demonstrate that
HCC may behave according to this novel prediction model,
and also suggest that type I tumors, that is tumors with an
ongoing antitumor immune response (high PD-L1 and high
TIL count), may be the ones to beneﬁt from PD-L1 or PD-1
blockade. Indeed, recent observations from clinical trials show
that patients who express PD-L1 are the ones that seem to ben-
eﬁt from anti-PD1 therapy.34 A similar prediction model might
be true for Gal-9 in HCC, as we show in Fig. 5B. We support
the idea that the use of TILs as a biomarker should be studied
in the context of the expression of immune inhibitory mole-
cules and that PD-L1 and Gal-9 are two of the molecules to be
taken into consideration.
While the tumor expression status of these molecules in
HCC has been reported, the expression of these molecules in
the surrounding TFL tissue is much less understood. While
PD-L1 and IDO have been shown, in single studies, to be
indeed expressed in TFL tissue of patients with HCC,13,58 that
has never been shown for Gal-9 or HVEM before. We here
show, both by immunohistochemistry and qPCR, that all four
immune inhibiting molecules are present in both the tumor
and the TFL compartments. We did not observe under-expres-
sion of mRNA levels in tumor tissue compared with TFL, while
such an under-expression was seen by IHC. Possible explana-
tions for the difference could be that we examined mRNA
expression only in 20 paired samples. Another explanation
could be translational and post-translational regulation of
mRNA. The presence of these molecules in the TFL tissue of
HCC patients may be explained by the production of cytokines
by the inﬁltrating lymphocytes.33,55-57 This observation suggests
that therapies targeting these molecules may not only enhance
antitumor immune responses but also anti-hepatitis-B virus or
anti-hepatitis-C virus immune responses and thereby contrib-
ute to viral clearance. Conversely, such treatments harbor the
theoretical danger of evoking undesired immunologic effects.
In our opinion, our study has several strong characteristics.
We have studied a homogenous group of patients, have studied
the expression of multiple immune inhibitory molecules in
tumor, as well as surrounding TFL, tissue and have validated
our ﬁndings in an independent cohort. Our study is the ﬁrst to
examine the co-expression of multiple immune inhibitory mol-
ecules in HCC. There are of course also limitations in our
study. Our selected panel of immune inhibitory molecules is by
no means exhaustive. We focused on molecules for which there
is solid evidence for their immune inhibitory role in cancer, for
which a reliable antibody was available for immunohistochem-
istry and for which the corresponding mechanism of interac-
tion with immune cells is well understood. However, as our
understanding of the immune inhibiting mechanisms of cancer
expands other molecules should be added. In addition, while
the use of TMAs to study such questions has clear beneﬁts,
such as the rapid analysis of large number of tissue cores over
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identical experimental conditions and preservation of valuable
patient tissue for future studies, there are also drawbacks. One
is the inability of TMAs to represent the complex spatial inter-
actions of immune inhibiting molecules in the complete tumor
microenvironment. For this reason, we did not evaluate the
expression of immune inhibitory molecules by TIL, as per-
formed, for PD-L1, in the study by Calderaro et al.,46 but
focused on the expression of these molecules in tumor cells.
Depending on the types of immune cells under study the rela-
tionship of expression of these molecules to outcome may be
affected.59 Another limitation of TMAs is that it is not ideal to
evaluate the presence of uncommon cell types. While CD8C
lymphocytes are abundant, FoxP3C T-regulatory cells are
much less common and thus more difﬁcult to systematically
evaluate using TMAs.
In conclusion, we show that low tumor expression of PD-L1
and Galectin-9, as well as low CD8CTIL count, are associated
with poor HCC-speciﬁc survival in patients with resected
HCC. PD-L1 and Galectin-9 expression in tumors may be
induced in response to immunologic pressure which may
explain why their presence is associated with prolonged sur-
vival. PD-L1 and Galectin-9 may be promising immunothera-
peutic targets in HCC patients with tumors expressing these
co-inhibitory molecules.
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